Literature DB >> 15347646

The Leber congenital amaurosis protein AIPL1 modulates the nuclear translocation of NUB1 and suppresses inclusion formation by NUB1 fragments.

Jacqueline van der Spuy1, Michael E Cheetham.   

Abstract

Mutations in the aryl hydrocarbon receptor-interacting protein-like 1 (AIPL1) cause the blinding disease Leber congenital amaurosis (LCA). The similarity of AIPL1 to AIP has led to suggestions that AIPL1 could function in a similar manner to AIP in facilitating protein translocation and as a component of chaperone complexes. AIPL1 interacts with the cell cycle regulator NEDD8 ultimate buster protein 1 (NUB1). As AIPL1 is predominantly cytoplasmic and NUB1 is predominantly nuclear, we tested the hypothesis that AIPL1 could modulate the nuclear translocation of NUB1. Co-transfection of AIPL1 with GFP-NUB1 resulted in a shift of GFP-NUB1 subcellular distribution toward the cytoplasm. Interestingly, AIPL1 was able to act in a chaperone-like fashion to efficiently suppress inclusion formation by NUB1 fragments. Co-transfection of AIPL1 with GFP-NUB1-N and GFP-NUB1-C resulted in an AIPL1-dependent suppression of GFP-NUB1-N perinuclear inclusions and GFP-NUB1-C intranuclear inclusions leading to the redistribution of these fragments in the cytoplasm. This chaperone-like function of AIPL1 was specific for NUB1, since AIPL1 was unable to suppress the inclusion formation by unrelated aggregation-prone proteins and AIP had no effect on NUB1 localization or inclusion formation. We examined the effect of a range of pathogenic and engineered mutations on the ability of AIPL1 to modulate NUB1 localization or inclusion formation. With the exception of W278X, which formed non-functional SDS-insoluble inclusions, all of the pathogenic mutations studied were soluble and could modulate NUB1 with varying efficiency compared with the wild-type protein. The effect of AIPL1 on NUB1 required the C-terminal region of AIPL1, as engineered C-terminal truncation mutations had no effect on NUB1. These data show that AIPL1 can modulate protein translocation and act in a chaperone-like manner and suggest that AIPL1 is an important modulator of NUB1 cellular function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15347646     DOI: 10.1074/jbc.M407871200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  NUB1 suppresses the formation of Lewy body-like inclusions by proteasomal degradation of synphilin-1.

Authors:  Kunikazu Tanji; Tomoaki Tanaka; Fumiaki Mori; Katsumi Kito; Hitoshi Takahashi; Koichi Wakabayashi; Tetsu Kamitani
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

2.  The Leber congenital amaurosis protein AIPL1 functions as part of a chaperone heterocomplex.

Authors:  Juan Hidalgo-de-Quintana; R Jane Evans; Michael E Cheetham; Jacqueline van der Spuy
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04-11       Impact factor: 4.799

3.  NEDD8 ultimate buster-1 long (NUB1L) protein promotes transfer of NEDD8 to proteasome for degradation through the P97UFD1/NPL4 complex.

Authors:  Shuai Liu; Hui Yang; Jian Zhao; Yu-Hang Zhang; Ai-Xin Song; Hong-Yu Hu
Journal:  J Biol Chem       Date:  2013-09-09       Impact factor: 5.157

4.  The ubiquitin-like modifier FAT10 inhibits retinal PDE6 activity and mediates its proteasomal degradation.

Authors:  Annika N Boehm; Johanna Bialas; Nicola Catone; Almudena Sacristan-Reviriego; Jacqueline van der Spuy; Marcus Groettrup; Annette Aichem
Journal:  J Biol Chem       Date:  2020-08-14       Impact factor: 5.157

5.  Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors.

Authors:  Mei Hong Tan; Alexander J Smith; Basil Pawlyk; Xiaoyun Xu; Xiaoqing Liu; James B Bainbridge; Mark Basche; Jenny McIntosh; Hoai Viet Tran; Amit Nathwani; Tiansen Li; Robin R Ali
Journal:  Hum Mol Genet       Date:  2009-03-19       Impact factor: 6.150

6.  The inherited blindness protein AIPL1 regulates the ubiquitin-like FAT10 pathway.

Authors:  John S Bett; Naheed Kanuga; Emma Richet; Gunter Schmidtke; Marcus Groettrup; Michael E Cheetham; Jacqueline van der Spuy
Journal:  PLoS One       Date:  2012-02-07       Impact factor: 3.240

7.  Leber congenital amaurosis associated with AIPL1: challenges in ascribing disease causation, clinical findings, and implications for gene therapy.

Authors:  Mei Hong Tan; Donna S Mackay; Jill Cowing; Hoai Viet Tran; Alexander J Smith; Genevieve A Wright; Arundhati Dev-Borman; Robert H Henderson; Phillip Moradi; Isabelle Russell-Eggitt; Robert E MacLaren; Anthony G Robson; Michael E Cheetham; Dorothy A Thompson; Andrew R Webster; Michel Michaelides; Robin R Ali; Anthony T Moore
Journal:  PLoS One       Date:  2012-03-06       Impact factor: 3.240

8.  Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations.

Authors:  X Sun; B Pawlyk; X Xu; X Liu; O V Bulgakov; M Adamian; M A Sandberg; S C Khani; M-H Tan; A J Smith; R R Ali; T Li
Journal:  Gene Ther       Date:  2009-08-27       Impact factor: 5.250

9.  Oculomotor deficits in aryl hydrocarbon receptor null mouse.

Authors:  Aline Chevallier; Antoine Mialot; Jean-Maurice Petit; Pedro Fernandez-Salguero; Robert Barouki; Xavier Coumoul; Mathieu Beraneck
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

Review 10.  Molecular chaperones and photoreceptor function.

Authors:  Maria Kosmaoglou; Nele Schwarz; John S Bett; Michael E Cheetham
Journal:  Prog Retin Eye Res       Date:  2008-03-29       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.